Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334255 · ClinicalTrials.gov registry record · Phase 1
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
A Phase 1 study, sponsored by Lpath.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01334255 is a Phase 1 study that was terminated before completion, run by Lpath. The registered enrollment target is 12 participants.
The verdict
NCT01334255, a Phase 1 study, was terminated before completion, sponsored by Lpath.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary to PED Secondary to Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV).
Interventions
- DRUG iSONEP (sonepcizumab/LT1009)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01334255
The ClinicalTrials.gov registry entry for NCT01334255 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lpath, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iSONEP (sonepcizumab/LT1009) is the first listed.
NCT01334255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01334255 about?
NCT01334255 is a clinical study titled "iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)". LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary to PED Secondary to Exudative Age-Related Macular Degeneration (AMD) or ...
What is the current status of trial NCT01334255?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01334255?
The interventions under investigation include: iSONEP (sonepcizumab/LT1009) (DRUG).
Who is sponsoring clinical trial NCT01334255?
This trial is sponsored by Lpath, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.